Organogenesis tests Vitrix in deep foot ulcers:
This article was originally published in Clinica
Executive Summary
Organogenesis has begun a US trial of its Vitrix skin replacement product in diabetic patients who have deep, non-healing wounds in their feet. Deep diabetic foot ulcers can extend through the layers of the skin to underlying bone, tendon or muscle. Vitrix, a single-layer product, can be folded upon itself and inserted into deep wounds. The Canton, Massachusetts firm already markets a skin substitute, Apligraf, for the treatment of diabetic foot and venous ulcers that do not extend below the layers of skin.